ArticleActa pharmaceutica Sinica. B2024
Combination of anti-inflammatory therapy and RNA interference by light-inducible hybrid nanomedicine for osteoarthritis treatment.
Article in Acta pharmaceutica Sinica. B, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Photothermally-activated nano-delivery system for on-demand treatment of diabetic wound infections.International journal of pharmaceutics: X · 2026Article
- Targeting Microglia-Neuron Crosstalk to Regulate Neuronal Excitability: Novel Translational Approaches for Chronic Pain Intervention.International journal of molecular sciences · 2026Review
- Review
- Nanomaterial-Based Photothermal Therapy for Inflammatory Diseases: Intervention Strategies, Synergistic Effects, and Future Challenges.International journal of nanomedicine · 2026Review
- PEG-NHInternational journal of nanomedicine · 2026Article
- Nanotechnology-driven strategies for gene therapy of arthritis.Materials today. Bio · 2025Review
- Harnessing Photo-Energy Conversion in Nanomaterials for Precision Theranostics.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- CRTAC1 derived from senescent FLSs induces chondrocyte mitochondrial dysfunctionActa pharmaceutica Sinica. B · 2025Article
- Protective effects of diacerein against quinolinic acid-induced Huntington's disease-like symptoms in adult zebrafish by targeting GSK-3β signalling.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Heat shock proteins in osteoarthritis: molecular mechanisms, pathogenic roles, and therapeutic opportunities.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a type of highly prevalent heterogeneous degenerative disease that leads to joint pain, deformity, the destruction of articular cartilage, and eventual disability. The current treatment strategies for OA often suffer from systemic side effects, poor anti-inflammatory efficacy, and persistent pain. To address these issues, we develop light-inducible nanomedicine that enables the co-delivery of anti-inflammatory drug (diacerein, DIA) and small interfering RNA (siRNA) targeting nerve growth factor (NGF) for pain relief to enhance the therapeutic efficacy of OA. The nanomedicine is based on poly(
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.